NASDAQ:CRGX - Nasdaq - US14179K1016 - Common Stock - Currency: USD
4.1
0 (0%)
The current stock price of CRGX is 4.1 USD. In the past month the price decreased by -9.09%. In the past year, price decreased by -80.35%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.84 | 323.71B | ||
AMGN | AMGEN INC | 13.09 | 146.07B | ||
GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
NTRA | NATERA INC | N/A | 20.94B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
BIIB | BIOGEN INC | 7.95 | 18.43B |
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. The company is headquartered in San Carlos, California and currently employs 167 full-time employees. The company went IPO on 2023-11-10. The company has a focused pipeline that includes its CRG-023 product candidate, a CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a range of B-cell malignancies with the goal of providing more patients with a durable complete response. Its latest program advancement, an allogeneic platform, is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. The universal allogeneic-enabling vector is intended to be paired with any CAR vector to create an allogeneic CAR T-cell therapy, with the potential to maintain the efficacy, durability, and safety of autologous cell therapy while broadening availability to more people with cancer.
CARGO THERAPEUTICS INC
835 Industrial Road, Suite 400
San Carlos CALIFORNIA US
Employees: 150
Phone: 16504998950
The current stock price of CRGX is 4.1 USD.
The exchange symbol of CARGO THERAPEUTICS INC is CRGX and it is listed on the Nasdaq exchange.
CRGX stock is listed on the Nasdaq exchange.
11 analysts have analysed CRGX and the average price target is 10.89 USD. This implies a price increase of 165.57% is expected in the next year compared to the current price of 4.1. Check the CARGO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CARGO THERAPEUTICS INC (CRGX) has a market capitalization of 189.05M USD. This makes CRGX a Micro Cap stock.
CARGO THERAPEUTICS INC (CRGX) currently has 150 employees.
CARGO THERAPEUTICS INC (CRGX) has a support level at 3.88 and a resistance level at 4.65. Check the full technical report for a detailed analysis of CRGX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CRGX does not pay a dividend.
CARGO THERAPEUTICS INC (CRGX) will report earnings on 2025-08-10.
CARGO THERAPEUTICS INC (CRGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.62).
The outstanding short interest for CARGO THERAPEUTICS INC (CRGX) is 5.72% of its float. Check the ownership tab for more information on the CRGX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CRGX. CRGX has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months CRGX reported a non-GAAP Earnings per Share(EPS) of -4.62. The EPS decreased by -56.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -40.45% | ||
ROE | -46.5% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 49% to CRGX. The Buy consensus is the average rating of analysts ratings from 11 analysts.